Novavax, Inc. (NVAX): Price and Financial Metrics
Novavax, Inc. (NVAX)
Today's Latest Price: $126.98 USD
Updated Jan 22 4:00pm
Add NVAX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
NVAX Stock Summary
- Price to trailing twelve month operating cash flow for NVAX is currently 125.1, higher than 95.69% of US stocks with positive operating cash flow.
- NVAX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.84% of US stocks.
- As for revenue growth, note that NVAX's revenue has grown 1,181.88% over the past 12 months; that beats the revenue growth of 99.34% of US companies in our set.
- Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are DRNA, CTMX, NKTR, XNCR, and AGIO.
- NVAX's SEC filings can be seen here. And to visit Novavax Inc's official web site, go to www.novavax.com.
NVAX Stock Price Chart Interactive Chart >
NVAX Price/Volume Stats
| Current price | $126.98 | 52-week high | $189.40 |
| Prev. close | $122.40 | 52-week low | $6.26 |
| Day low | $121.43 | Volume | 2,598,500 |
| Day high | $127.21 | Avg. volume | 3,223,671 |
| 50-day MA | $115.69 | Dividend yield | N/A |
| 200-day MA | $93.32 | Market Cap | 8.08B |
Novavax, Inc. (NVAX) Company Bio
Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.
NVAX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $126.98 | $27645.64 | 22008% |
Below please find a table outlining a discounted cash flow forecast for NVAX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novavax Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 22116%; returns of such proportions should be viewed with some skepticism, though. The most interesting components of our discounted cash flow analysis for Novavax Inc ended up being:
- The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.74% of the free cash flow producing stocks we're observing.
- Novavax Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -17.58. This coverage rate is greater than that of only 5.84% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- As a business, Novavax Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 21574% |
| 1% | 21791% |
| 2% | 22008% |
| 3% | 22224% |
| 4% | 22441% |
| 5% | 22658% |
Want more companies with a valuation profile/forecast similar to that of Novavax Inc? See THC, BMRN, KMDA, VRTX, and AMEH.
Loading social stream, please wait...